Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com
  • 5,0 (1)
  • SỨC KHỎE & THỂ DỤC

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. Heat shock protein-derived peptides and autoimmunity in glaucoma

    2 GIỜ TRƯỚC

    Heat shock protein-derived peptides and autoimmunity in glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/heat-shock-protein-derived-peptides-and-autoimmunity-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Heat Shock Proteins and Immune Responses in Glaucoma Glaucoma is a leading cause of irreversible vision loss, affecting tens of millions of people worldwide (). Normally, glaucoma is linked to high eye pressure, but many patients – especially those with normal-tension glaucoma – have nerve damage despite normal pressure. This has led researchers to look beyond pressure and investigate the immune system’s role. In particular, eye experts have focused on heat shock proteins (HSPs), which are stress-related proteins that help keep nerve cells alive. Under some conditions these HSPs themselves may become targets of the immune system, contributing to nerve damage (). Evidence suggests that T cells (a type of white blood cell) reacting against HSPs can harm the optic nerve. For example, patient studies have found abnormally high levels of antibodies (proteins made by immune B cells) against HSPs in many glaucoma patients. In fact, multiple studies report that glaucoma patients often have elevated serum autoantibodies to HSP27 and HSP60, two common HSPs () (). In the lab, adding these patient antibodies to retinal cells can trigger cell death (), suggesting they are not just markers but may be damaging. In eye fluid (aqueous humor), glaucoma patients also show unique autoantibody “fingerprints,” including unusually high anti–HSP27 levels compared to healthy controls (). Taken together, these human findings point to an autoimmune tendency against HSPs in glaucoma. Evidence from Animal Models Studies in animals strongly support the idea that HSP-specific immune reactions can cause glaucoma-like damage. In classic experiments, scientists immunized healthy rats with HSP-derived peptides (for example, pieces of HSP27 or HSP60). Remarkably, these rats later developed nerve damage very similar to glaucoma () (). For instance, Wax and colleagues (2008) found that rats given HSP27 or HSP60 peptides lost large numbers of retinal ganglion cells (RGCs) – the neurons that form the optic nerve – and their axons in a pattern that closely mimics human glaucoma (). This damage occurred even though eye pressure stayed normal. Another group confirmed that immunizing rats with an optic-nerve extract (which contains many antigens, including HSPs) similarly caused RGC death and optic nerve thinning (). Importantly, these models also showed earlier immune changes: T cells infiltrated the retina days after immunization, and support cells (microglia) became activated, long before the neurons started dying () (). These animal experiments provide direct proof that an HSP-driven immune response can cause glaucoma-like neurodegeneration. Autoantibody Profiles in Patients Studies of glaucoma patients have found immune “signatures” consistent with HSP involvement. Many patients (especially with normal-tension glaucoma) carry autoantibodies against retina and optic nerve proteins, including HSPs () (). For example, researchers have detected antibodies to HSP27 and HSP60 in the blood of these patients (). In postmortem analyses, donor retinas from glaucoma patients showed antibody binding to HSP27 and HSP60 (). Laboratory tests imply these antibodies could be harmful: when anti-HSP27 antibodies from patients are applied to living retinal cells, Support the show

    12 phút
  2. Endothelin pathway peptides and optic nerve head ischemia in glaucoma

    13 GIỜ TRƯỚC

    Endothelin pathway peptides and optic nerve head ischemia in glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/endothelin-pathway-peptides-and-optic-nerve-head-ischemia-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Endothelin-1 and Glaucoma: Blood Flow, Astrocytes, and Therapy Endothelin-1 (ET-1) is a very strong vasoconstrictor (makes blood vessels tighten) found naturally in the body. In the eye, ET-1 levels and signaling have been linked to damage in glaucoma, a disease of the optic nerve. Glaucoma often involves high intraocular pressure (IOP), but other factors – especially reduced blood flow and oxygen (ischemia) at the optic nerve head – can contribute. ET-1 can narrow small blood vessels around the optic nerve and in the retina, leading to poor oxygen supply. It also affects astrocytes, the support cells of the optic nerve, which can become overactive when stressed. In this article, we explain how ET-1 and its receptors (called ETA and ETB) are involved in glaucoma, how ET-1 interacts with nitric oxide (a blood‐vessel relaxer), evidence that ET-1 levels are higher in glaucoma patients, and finally how blocking ET-1 receptors might help protect the eye (along with the challenges of such treatments). How ET-1 Affects Eye Blood Flow ET-1 is produced by many eye tissues (retina, ciliary body, trabecular meshwork, etc.). It normally helps regulate blood flow and aqueous humor outflow. However, high ET-1 causes excessive vasoconstriction. For example, human lab studies found that injecting ET-1 into the eye rapidly decreases blood flow in the retina and optic nerve head (). Blood vessel narrowing leads to local ischemia (low oxygen), which can injure retinal ganglion cell (RGC) axons. ET-1 even has a direct toxic effect: it can trigger RGCs to undergo apoptosis (cell death) () (). Astrocytes – star-shaped glial cells in the optic nerve – also respond to ET-1. When ET-1 is high, astrocytes can multiply and change shape (a process called astrogliosis). This reactive gliosis can further harm the optic nerve environment. In lab cultures, ET-1 causes optic nerve astrocytes to proliferate, and this effect is blocked by either ETA or ETB receptor inhibitors (). In glaucomatous optic nerves (from humans and animals), researchers have observed more astrocyte proliferation and GFAP (a stress protein) when ET-1 is elevated (). Nitric Oxide and ET-1: Balancing Vessel Tone In healthy eyes, nitric oxide (NO) and ET-1 balance each other. NO is a vasodilator (it widens vessels), whereas ET-1 constricts them. Endothelial cells lining blood vessels release NO under normal conditions, relaxing the vessel walls (). Any disturbance in this balance – for example, too much ET-1 or too little NO – can impair blood flow. In the human ophthalmic (eye) artery, experiments showed that blocking NO causes vessels to constrict and that adding ET-1 causes strong constriction (). Thus, ET-1’s vasoconstriction can overcome NO’s dilating effect. Indeed, in glaucoma, impaired NO production (often due to endothelial dysfunction) is thought to worsen ET-1–induced ischemia. In some studies, giving ET-1 to people or animals reduced NO-mediated blood flow significantly, and an ETA-blocker (like BQ-123) could prevent that reduction (). This cross-talk means that high ET-1 disrupts the normal NO-driven relaxation, promoting a harmful cycle of poor blood supply. ET-1 Receptors: ETA and ETB Signaling ET-1 works by binding two main receptors on cells, Support the show

    14 phút
  3. MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

    1 NGÀY TRƯỚC

    MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/mots-c-and-glaucoma-a-mitochondrial-signal-with-bigger-implications-than-eye-pressure Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS-c Is In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (). MOTS-c levels rise in response to stress or exercise and decline with age (). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (). MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal () (). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria. MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (). It can also activate NRF2 pathways, which turn on antioxidant defenses () (). In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation () (). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions () (). However, its role in eye diseases (especially glaucoma) is not established. Why Glaucoma Might Intersect with MOTS-c Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does: Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.) Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure i Support the show

    21 phút
  4. Senolytics and the Glaucoma Niche: Clearing Old Cells for Longer-Life Signals

    2 NGÀY TRƯỚC

    Senolytics and the Glaucoma Niche: Clearing Old Cells for Longer-Life Signals

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/senolytics-and-the-glaucoma-niche-clearing-old-cells-for-longer-life-signals Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Glaucoma is an age-related eye disease in which high pressure in the eye (intraocular pressure, or IOP) damages retinal nerve cells and leads to vision loss. Aging is the single biggest risk factor for glaucoma, and new research suggests this may be because aging eyes accumulate senescent cells – cells that have permanently stopped dividing and secrete inflammatory signals. Cellular senescence is a normal response to damage or stress, but when these old cells build up they release a mix of molecules called the senescence-associated secretory phenotype (SASP). SASP factors include inflammatory cytokines (like interleukin-6), growth factors (like TGF-β) and enzymes that remodel tissue. In eye tissues such as the trabecular meshwork (TM) (the drainage canal that controls IOP) and the optic nerve head (ONH) (where retinal ganglion cell axons exit the eye), senescent cells and their SASP appear to drive chronic inflammation and scarring. For example, one recent review noted that both TM cells and retinal ganglion cells in aging eyes show markers of senescence, and clearing those old cells improved retinal ganglion cell survival in animal models () (). This article reviews the evidence that senescence contributes to glaucoma and explores how senolytic therapies – drugs that specifically kill senescent cells – might help protect the eye. Senescence in the Glaucoma Niche Trabecular Meshwork Senescence The trabecular meshwork (TM) is a sponge-like tissue that drains fluid from the eye. With normal aging, TM cell numbers gradually decline and the meshwork develops thick, stiff extracellular material. Histological studies show that older eyes have far fewer TM cells than young eyes, and this loss is much greater in glaucoma patients (). When TM cells die or senesce and are replaced by scar-like matrix, the drainage channel narrows and IOP rises (). In fact, Zhang et al. describe how an “absence of TM cells, followed by their replacement with extracellular matrix, leads to increased resistance to fluid outflow” (). This fits with clinical observations that the aging outflow pathway becomes fibrotic (for example, accumulation of type VI collagen is seen in glaucomatous TM) and raises IOP (). Laboratory studies of TM cells have identified classic features of senescence in aging or stressed cells: enlarged shape, cell-cycle arrest, and expression of markers like p16^INK4a. Importantly, senescent TM cells unleash pro-inflammatory SASP factors. For example, senescent TM cells have been shown to overproduce interleukin-6 (IL-6), IL-8 and chemokines (CCL2, CXCL3) (). These cytokines can recruit immune cells and drive fibrotic signaling (notably TGF-β is also part of the ocular SASP). Such chronic inflammation likely stiffens the TM. In short, aged and diseased TM tissue accumulates senescent cells that secrete fibrosis-inducing signals, contributing to outflow obstruction and elevated IOP () (). Optic Nerve Head and Retina Senescence Glaucoma also damages the optic nerve head (ONH) and retinal ganglion cells (RGCs) that send signals from the eye to the brain. Aging affects these tissues too. RGCs in older eyes show more oxidative damage and are less able to survive stress (). Senescent cells Support the show

    15 phút
  5. Ketogenic Signals and Beta-Hydroxybutyrate: IOP, Neuroprotection, and Longevity Intersections

    4 NGÀY TRƯỚC

    Ketogenic Signals and Beta-Hydroxybutyrate: IOP, Neuroprotection, and Longevity Intersections

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/ketogenic-signals-and-beta-hydroxybutyrate-iop-neuroprotection-and-longevity-intersections Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Ketogenic Diet and Retina: Protecting Eye Nerves through Metabolism Glaucoma is an eye disease where pressure or other factors cause progressive damage to the retinal nerve cells (retinal ganglion cells, RGCs) and their fibers, leading to vision loss. Traditionally, treatment focuses on lowering eye pressure (intraocular pressure, IOP). Recently, researchers have explored whether changing body metabolism – for example with a ketogenic diet or ketone supplements – could help protect RGCs. A ketogenic diet is very low in carbohydrates and high in fats. In response, the body burns fat and produces ketone bodies (like beta-hydroxybutyrate or BHB) as a fuel. Ketones can serve as an alternative energy source for the brain and eyes. Emerging evidence suggests these metabolic changes can boost cell energy use, quiet harmful overactivity (excitotoxicity), and even alter gene activity, in ways that may shield RGCs from damage () (). In animal studies, ketone treatments have improved RGC survival and function. In other model systems, BHB shows broad anti-inflammatory and “longevity” effects. In this article we explain these findings in plain terms, and discuss what they mean for glaucoma patients – especially those who are older or have other health issues. Fueling Mitochondria: Energy Efficiency and Retinal Health The retina, especially RGCs, is a highly active tissue that needs a lot of energy to work. This energy comes from tiny structures in cells called mitochondria. If mitochondria work better, nerve cells are healthier. Ketones are a special fuel for mitochondria. They can be turned into energy efficiently, sometimes even more cleanly than sugar. A number of studies have shown that ketogenic metabolism boosts mitochondrial function. For example, one study in mice used a glaucoma model and found that a ketogenic diet promoted both mitochondrial biogenesis (making new mitochondria) and mitophagy (recycling damaged mitochondria) in RGCs (). In that glaucoma model, mice eating a high-fat, low-carb diet kept more RGCs alive than control mice. The investigators noted increased mitochondrial markers and better energy balance in those cells () (). In simpler terms, the ketogenic diet gave the eye nerves a metabolic “upgrade” – more and healthier mitochondria that could meet energy needs under stress. Animal research also links ketosis to better antioxidant defenses (fighting cell damage). For example, a scientific review points out that ketogenic metabolism can lower production of harmful reactive oxygen species, and boost cell-protective pathways () (). In experimental glaucoma (an inherited model in DBA/2J mice), mice on a ketogenic diet showed healthier mitochondria and more antioxidant response compared to controls (). These changes were accompanied by better RGC survival. This suggests that providing ketones – either through diet or supplements – may make retinal neurons more energy-efficient and resistant to stress () (). Calming Excitotoxicity: Dampening Overactive Nerve Signals Another stress factor for neurons is excitotoxicity. This happens when too much glutamate (a common nerve messenger) overexcites cells and leads to injury. In glaucoma and other neurod Support the show

    16 phút
  6. The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

    5 NGÀY TRƯỚC

    The Glaucoma Energy Crisis: How Pyruvate Rescues Failing Eyes (And Why Your Fitness Level Matters)

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-glaucoma-energy-crisis-how-pyruvate-rescues-failing-eyes-and-why-your-fitness-level-matters Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Demand-Driven Metabolism: Why 3g of Pyruvate Won’t “Rev Up” a Couch Potato Your cells are like a precisely-tuned factory, only cranking out ATP (the cellular “energy currency”) when there’s work to do. If you’re sedentary and not using extra energy, simply swallowing a few grams of pyruvate won’t flood cells with power. In fact, cells regulate their energy supply very tightly. High levels of ATP actually shut down key energy pathways: for example, abundant ATP inhibits the enzyme pyruvate dehydrogenase (PDH) and instead activates pyruvate carboxylase (). In plain terms, if the “battery” (ATP) is already full, the cell stops using fuel. Extra pyruvate then gets shunted into storage or recycled rather than magically generating a feeling of buzz. In short, cellular energy production is strictly demand-driven. Even if you load up on pyruvate, an inactive body won’t convert it to extra ATP unless it’s needed. Instead, the surplus pyruvate enters normal metabolic “overflow” routes, including: Gluconeogenesis (Glucose Synthesis): In the liver, pyruvate (often via lactate) can be converted back into glucose to maintain blood sugar levels. This involves carboxylating pyruvate to oxaloacetate and eventually making glucose (). It’s an energy-intensive process – the body won’t do it without reason. Lactate Cycle: Excess pyruvate in muscles can be turned to lactate, which is shuttled to the liver and made into glucose, recycling energy. This prevents a build-up of metabolic waste and helps maintain blood glucose in rest. Fat Synthesis (Minor Route): Only in situations of chronic, massive over-supply does pyruvate contribute to fat. Experimentally, adipose tissue barely converts pyruvate into fatty acids unless its concentration is extremely high (tens of mM) (). In practical terms, a 3 g supplement won’t flood your blood with enough pyruvate to trigger significant fat storage. Gastrointestinal Effects: Strong organic acids can upset the stomach if overdone. High supplemental doses (dozens of grams) are known to cause gas, bloating or diarrhea (). In most studies, moderate doses (a few grams) are well-tolerated, but any abrupt high-dose intake could irritate the gut. The bottom line: If your cells don’t need more ATP, extra pyruvate is either turned back into sugar (used later) or simply stored without giving you a noticeable energy boost. The body won’t just burn it for no reason, and at high doses one might just feel tummy trouble (). The Glaucoma Energy Crisis: A Localized Shortage in the Retina In glaucoma, the optic nerve – built from retinal ganglion cells (RGCs) – faces a unique energy bottleneck. RGCs are extreme energy hogs: they fire constantly, maintain big voltage differences, and transmit visual signals non-stop. In fact, the retina is physiologically the most energy-hungry tissue in the body () (). One review notes that “the retina is the highest oxygen-consuming organ in the human body” and inner retinal neurons (like RGCs) have “the highest metabolic rate of all central nervous tissue” (). Simply put, RGCs are like high-powered computers that never sleep. They need large ATP supplies just to keep their ion pumps running and signals flowing (). With age and g Support the show

    11 phút
  7. Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

    5 NGÀY TRƯỚC

    Photobiomodulation (670 nm) for Aging Retina: Lifespan Signals from Flies to Mammals

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/photobiomodulation-670-nm-for-aging-retina-lifespan-signals-from-flies-to-mammals Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction As we age, eye cells gradually lose energy and function, partly because their mitochondria (the cell’s “batteries”) become weaker (). This is true in the retina – the light-sensitive tissue at the back of the eye – where dying mitochondria contribute to poorer vision and diseases like age-related macular degeneration (AMD). Photobiomodulation (PBM) is a gentle therapy that uses low-intensity red or near-infrared light (usually around 670 nm wavelength) to stimulate cells. Laboratory studies suggest that shining 670 nm light into the eye can recharge mitochondrial function, boosting energy (ATP) production and easing inflammation () (). In practical terms, this therapy is often done with LED lamps or lasers positioned near the eye for a few minutes each day. Early experiments – from simple flies to mice and small human trials – hint that PBM might improve retinal health and even aspects of whole-body aging. This article reviews how 670 nm light benefits photoreceptors and retinal ganglion cells, summarizes results in experimental models (including lifespan effects in insects), and discusses dosing, safety, and possible home use. Finally, we suggest future studies that combine vision tests with markers of mitochondrial health to see if this light can boost not just eyesight, but overall cellular “youth.” How near-infrared light boosts retinal cells Photobiomodulation at 670 nm targets mitochondria, the tiny structures inside cells that make most of our energy (ATP). In mitochondria, a key enzyme called cytochrome c oxidase absorbs red/near-infrared light, which helps it run more efficiently () (). In effect, 670 nm light raises the electrical membrane potential of mitochondria and lets them crank out more ATP () (). Studies show this extra energy relieves age-related decline: for example, one report found that a month of daily 670 nm light in old mice roughly corrected their low mitochondrial membrane potential and ATP levels (). In addition, energized mitochondria produce fewer harmful free radicals, so treated cells show less oxidative stress and inflammation () (). Photoreceptors (the retina’s light-sensing rods and cones) and retinal ganglion cells (RGCs, the nerves that carry visual signals to the brain) are high-energy cells packed with mitochondria. By boosting mitochondrial activity, 670 nm light helps these cells work more efficiently. Lab studies find that photobiomodulation can directly improve photoreceptor metabolism and survival. For instance, in a mouse model of light-induced retinal damage, 670 nm treatment greatly improved photoreceptor health: treated cells had stronger mitochondrial respiration and less stress-induced damage (). Likewise, in an optic-nerve injury model, 670 nm light preserved RGCs: treated rats showed a 3.4-fold increase in visual signal strength and 1.6 times more surviving RGCs, along with higher retinal ATP levels and antioxidant markers (). In summary, by dialing up mitochondrial efficiency in these retina cells, photobiomodulation can make aged or stressed eye cells behave more like young, healthy ones. Results from animal studies Researchers have tested 670 nm PBM in various aging and disease models with encouraging results. In aged mic Support the show

    13 phút
  8. What’s New in Glaucoma Research in April 2026? What Patients Should Know

    15 THG 4

    What’s New in Glaucoma Research in April 2026? What Patients Should Know

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/what-s-new-in-glaucoma-research-in-april-2026-what-patients-should-know Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: What’s New in Glaucoma Research in April 2026? What Patients Should Know Glaucoma is a group of eye diseases that slowly damage the optic nerve, often due to high pressure inside the eye. It’s sometimes called the “silent thief of sight,” because vision can go gradually without you noticing (). Worldwide, glaucoma is a leading cause of irreversible blindness – in fact it’s the second-most common cause of blindness globally (after cataracts) (). Researchers are always looking for new clues about how it works and how to catch or treat it earlier. In April 2026, several new studies made headlines. We explain them in plain language below. (For context, note that a January 2026 study found the enzyme GPX4 – glutathione peroxidase 4 – helps protect eye nerve cells from damage (). But that study is from January, not the April updates.) Tiny Blood Vessel Leaks and Glaucoma Damage What the study found: A new research report suggests that tiny leaks in tiny blood vessels in the eye may contribute to glaucoma damage. In simple terms, researchers observed that microscopic blood vessels in the retina (the back of the eye) can become slightly leaky. This leak could let fluid or blood components escape into parts of the eye where they shouldn’t be. Over time, such leaks might stress or damage the optic nerve fibers. (Think of it like very small blood vessel “drips” that harm delicate tissue nearby.) Why it matters: We usually think of glaucoma damage as due to pressure; this study hints that blood vessel health is also important. If true, it could open new treatment ideas (for example, medicines to strengthen those vessels or reduce leakage). It’s an unusual idea in glaucoma research, so it’s still early-stage. It reminds us that glaucoma might involve more than just simple pressure – the circulation in the eye may play a role. How it was studied: This kind of research is usually done in laboratory models (animals or cell/tissue tests), not yet in people. The study did tests on eye tissue (or possibly in animals) to look for leaks under a microscope. (Because it’s new and detailed work, it’s not a large human trial.) Patient impact now: Right now, this finding does not change how we treat glaucoma. It’s a clue in the lab. Patients should continue their usual pressure-lowering treatments. In the future, if this line of research pans out, doctors might test additives that protect those tiny vessels. Big-picture importance: On a scale of 1–10 (10 = game-changing, 1 = interesting but small), this gets about a 5/10. It’s intriguing because it suggests a new mechanism, but it’s still early. More research will be needed to know if vessel leaks are a major factor in most glaucoma cases or only a minor one. A Possible Nerve-Protecting Drug (WAY-100635) What the study found: Another April 2026 study looked at a drug called WAY-100635 (pronounced “way-ten-thousand-six-hundred-thirty-five”). This compound affects serotonin receptors in the brain, but researchers tested it to see if it could protect eye nerve cells. In lab tests, giving WAY-100635 seemed to shield retinal ganglion cells (the neurons that form the optic nerve) from damage caused by glaucoma-like stress. In other words, in their experiments, eyes Support the show

    9 phút
Xem tất cả (159)

Giới Thiệu

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Thông Tin

Có Thể Bạn Cũng Thích